The 52-Year-Old with Prediabetes Who Wants 'the Shot'
A 52-year-old man with BMI 33, A1c 6.2%, and a strong family history of type 2 diabetes asks about a GLP-1 medication he saw advertised for weight loss. He has no diabetes, no pancreatitis history, and no personal or family history of medullary thyroid carcinoma or MEN2. He exercises twice weekly and has tried 'cutting carbs' for three months with 2 kg loss. His blood pressure is 128/78, LDL 118, and he takes no medications. He is motivated but wants to know if he 'qualifies' and whether he should wait until he actually has diabetes.
1. Is he a candidate for pharmacotherapy for weight, and what is the reasoning?
Read the worked answer
He has obesity (BMI ≥30), which is itself a treatment indication for anti-obesity pharmacotherapy; he does not need diabetes to 'qualify.' The judgment tested is distinguishing weight-loss medication indications from diabetes indications. He has a comorbidity-free obesity but a high-risk trajectory (prediabetes, family history, central adiposity), which strengthens the case. However, the first-line step is still intensive lifestyle intervention (≥6 months of structured nutrition/physical activity), and he has only had a modest self-directed attempt. A reasonable plan: intensify lifestyle with a structured program and consider pharmacotherapy now or after a defined 3–6 month trial, depending on shared decision-making. If choosing a GLP-1, screen for contraindications (MTC/MEN2, pancreatitis, gastroparesis) and counsel on GI side effects, cost, and the need for long-term use-weight regain is common on discontinuation.
2. What else should be addressed at this visit beyond weight?
Read the worked answer
Prediabetes: annual A1c, and consider that ≥7% weight loss reduces progression to diabetes by roughly half in trial populations. Cardiovascular risk: calculate 10-year ASCVD risk; at his age and risk factors, statin consideration depends on the pooled estimate-if 10-year risk is ≥7.5% or if risk-enhancing factors are present, discuss a moderate-intensity statin. Blood pressure is normal. Screen for sleep apnea given BMI and ask about symptoms. Vaccinations and colorectal cancer screening (age 45+) should be current. The exam-relevant judgment is that obesity treatment is not cosmetic-it is cardiometabolic prevention-and that a single A1c and BMI do not replace a full risk assessment.